1. Phase II study on the combination of irinotecan plus cisplatin as a second-line therapy in patients with advanced or recurrent gastric cancer
   YASUSHI RINO et al, 2013, Molecular and Clinical Oncology CrossRef
2. A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
   Arthur Lui et al, 2018, Investigational New Drugs CrossRef
3. How May Ramucirumab Help Improve Treatment Outcome for Patients with Gastrointestinal Cancers?
   Ming-Huang Chen et al, 2021, Cancers CrossRef
4. Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer
   Liuting Yang et al, 2018, BMC Gastroenterology CrossRef